Prolonged cell treatment with mTOR inhibitor rapamycin leads to the development of resistance. Exosomes of resistant cells induce the resistance to rapamycin in the parent MCF-7cells. Exosome-induced resistance reproduces the changes revealed in the rapamycin-resistant cells, including the activation of ERK/AP-1.